Alternative splicing of the RAGE cytoplasmic domain regulates cell signaling and function

PLoS One. 2013 Nov 8;8(11):e78267. doi: 10.1371/journal.pone.0078267. eCollection 2013.

Abstract

The Receptor for Advanced Glycation End-products (RAGE) is a multi-ligand receptor present on most cell types. Upregulation of RAGE is seen in a number of pathological states including, inflammatory and vascular disease, dementia, diabetes and various cancers. We previously demonstrated that alternative splicing of the RAGE gene is an important mechanism which regulates RAGE signaling through the production of soluble ligand decoy isoforms. However, no studies have identified any alternative splice variants within the intracellular region of RAGE, a region critical for RAGE signaling. Herein, we have cloned and characterized a novel splice variant of RAGE that has a truncated intracellular domain (RAGEΔICD). RAGEΔICD is prevalent in both human and mouse tissues including lung, brain, heart and kidney. Expression of RAGEΔICD in C6 glioma cells impaired RAGE-ligand induced signaling through various MAP kinase pathways including ERK1/2, p38 and SAPK/JNK. Moreover, RAGEΔICD significantly affected tumor cell properties through altering cell migration, invasion, adhesion and viability in C6 glioma cells. Furthermore, C6 glioma cells expressing RAGEΔICD exhibited drastic inhibition on tumorigenesis in soft agar assays. Taken together, these data indicate that RAGEΔICD represents a novel endogenous mechanism to regulate RAGE signaling. Significantly, RAGEΔICD could play an important role in RAGE related disease states through down regulation of RAGE signaling.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alternative Splicing / physiology*
  • Animals
  • Cell Line, Tumor
  • Humans
  • Mice
  • Organ Specificity / physiology
  • Protein Structure, Tertiary
  • Rats
  • Receptor for Advanced Glycation End Products
  • Receptors, Immunologic / biosynthesis*
  • Receptors, Immunologic / genetics
  • Signal Transduction / physiology*

Substances

  • Receptor for Advanced Glycation End Products
  • Receptors, Immunologic

Grants and funding

The work presented here is funded by lab startup funds from the University of Miami. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.